# Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

> **NCT03613428** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 12 (estimated)

## Conditions studied

- Acute T Cell Leukemia

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03613428
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2018-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03613428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03613428, "Ruxolitinib Plus LVP in Patients With R/R ETP-ALL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03613428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*